Literature DB >> 29990695

Recovery of circulating CD56dim NK cells and the balance of Th17/Treg after nucleoside analog therapy in patients with chronic hepatitis B and low levels of HBsAg.

Nianqiu Liu1, Bin Liu1, Li Zhang1, Hu Li1, Zhiwei Chen1, Aoran Luo1, Min Chen1, Mingli Peng1, Wenwei Yin1, Hong Ren1, Peng Hu2.   

Abstract

BACKGROUND AND AIMS: Much evidence indicates that the soluble antigens secreted by hepatitis B virus (HBV) inhibit the function of the immune system. The aim of this study is to investigate, after treatment with nucleoside (acid) analogs (NAs) and the inhibition of viral replication, whether the immune systems of patients with a peripheral blood HBV-DNA level <1000 IU/mL, hepatitis B e antigen (HBeAg) disappearance, and a decrease in hepatitis B surface antigen (HBsAg) levels could be reconstructed.
METHODS: The frequency and phenotype of circulating natural killer (NK) cells, dendritic cells (DCs), T-helper (Th) cells, regulatory T (Treg) cells, CD4+, CD8+ T cells, T follicular helper (Tfh) cells and B cells subtypes were tested by flow cytometry in chronic hepatitis B (CHB) patients and healthy controls (HCs). The levels of HBV-related serum HBsAg, HBeAg, HBV-DNA load, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were determined.
RESULTS: Regarding the innate immune system, an increased frequency of CD56dim NK cells was found in the therapeutic response (TR) group compared with that in the immune-active phase (IA) group. Additionally, regarding the adaptive immune system, the Th17/CD4+CD25+CD127dimTreg ratio was reduced in the TR group. Additionally, the frequency of CD40L+CXCR5+CD4+T cells and CD40+CD19+CD27+CD38+B cells was significantly higher than that of HCs, while that of PDL1+CD19+ B cells was lower. Furthermore, the frequencies of CTLA4+CD4+T cells and CTLA4+CD8+T cells in patients with CHB were significantly higher than those in HCs.
CONCLUSION: After NA treatment and the inhibition of viral replication, circulating CD56dim NK cells and the balance of Th17/Treg can be recovered. Restoring circulating CD56dim NK cells and the Th17/Treg balance may help reduce HBsAg levels in patients.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hepatitis B virus; Natural killer cells; Nucleoside analogs; Regulatory T cells; T-helper cells

Mesh:

Substances:

Year:  2018        PMID: 29990695     DOI: 10.1016/j.intimp.2018.06.043

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  5 in total

1.  Combination of pegylated interferon-alpha and nucleos(t)ide analogue treatment enhances the activity of natural killer cells in nucleos(t)ide analogue experienced chronic hepatitis B patients.

Authors:  X Pang; L Zhang; N Liu; B Liu; Z Chen; H Li; M Chen; M Peng; H Ren; P Hu
Journal:  Clin Exp Immunol       Date:  2020-07-24       Impact factor: 4.330

2.  Effect of Antiviral Therapy During Pregnancy on Natural Killer Cells in Pregnant Women With Chronic HBV Infection.

Authors:  Fuchuan Wang; Si Xie; Chongping Ran; Hongxiao Hao; Tingting Jiang; Wen Deng; Xiaoyue Bi; Yanjie Lin; Liu Yang; Fangfang Sun; Zhan Zeng; Yao Xie; Minghui Li; Wei Yi
Journal:  Front Immunol       Date:  2022-05-23       Impact factor: 8.786

Review 3.  Coronavirus Disease 2019 Vaccinations in Patients With Chronic Liver Disease and Liver Transplant Recipients: An Update.

Authors:  Pimsiri Sripongpun; Nawamin Pinpathomrat; Jackrapong Bruminhent; Apichat Kaewdech
Journal:  Front Med (Lausanne)       Date:  2022-06-22

4.  [Effects of hepatitis B virus on Th17, Treg and Th17/Treg ratio in different alanine aminetransferase stages].

Authors:  P Gao; Y P Luo; J F Li; I Chen; X R Mao
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2022-04-18

5.  Outcomes of Cessation of Antiviral Therapy in Chronic Hepatitis B: A Retrospective Cohort Study.

Authors:  Pinar Ergen; Burcu Isik; Ferhat Arslan; Fatma Yılmaz Karadag; Ozlem Aydin; Yasemin Cag; Saadet Yazici; Ayse Canan Ucisik; Mustafa Haluk Vahaboglu
Journal:  Medeni Med J       Date:  2021-09-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.